Study Showed Patients Using COPAXONE® Had Significantly Lower Risk of Relapse and Lower Medical Costs Compared to Patients Using Rebif® in Relapsing-Remitting Multiple ... more »
|
|||||
|
Multiple Sclerosis Info
|
Thursday, November 1
Study: Copaxone verses Rebif for relapse rate and cost
by
multiplesclerosis
on Thu 01 Nov 2007 12:00 AM CST
|
||||